ANNEXON, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
ANNEXON, INC. (ANNX) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-12
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $1.15M.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $909.00K.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-09-30 was $697.00K.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-06-30 was $480.00K.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $1.06M, a 30.69% decline from fiscal 2024.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $1.53M.
- ANNEXON, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $7.99M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|
| 2026-06-30 | $1.15M 10-Q · filed 2026-08-12 | $2.06M derived: sum of 2 quarters · filed 2026-08-12 | |
| 2026-03-31 | $909.00K 10-Q · filed 2026-08-12 | ||
| 2025-12-31 | $1.06M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $697.00K 10-Q · filed 2025-11-10 | ||
| 2024-12-31 | $1.53M 10-K · filed 2026-03-30 | ||
| 2024-06-30 | $480.00K 10-Q · filed 2025-11-10 | $1.41M derived: sum of 2 quarters · filed 2025-11-10 | |
| 2024-03-31 | $933.00K 10-Q · filed 2025-11-10 | ||
| 2023-03-31 | $525.00K 10-Q · filed 2023-11-13 | ||
| 2022-12-31 | $7.99M 10-K · filed 2023-03-06 | ||
| 2022-09-30 | $9.50M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |